Clarity Pharmaceuticals Ltd (ASX:CU6 – Get Free Report) insider Rosanne Robinson acquired 178,079 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were bought at an average cost of A$0.93 ($0.63) per share, for a total transaction of A$165,079.23 ($113,067.97).
Clarity Pharmaceuticals Price Performance
Clarity Pharmaceuticals Company Profile
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2.
Recommended Stories
- Five stocks we like better than Clarity Pharmaceuticals
- Insider Trading – What You Need to Know
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 3 Best Fintech Stocks for a Portfolio Boost
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Clarity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
